Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

We are pleased to announce Prof Arturo Reyes-Sandoval’s project application to the MRC-DPFS scheme entitled "A novel P. vivax pre-erythrocytic malaria vaccine for broad coverage: Progression to GMP manufacture of a clinical vaccine lot" has been Awarded in Principle.

Medical Research Council logoThis is a £2M Award (subject to final negotiations) that will allow the Reyes Group to move a step closer to the final stages of the clinical trials for their P. vivax vaccine.

 The DPFS (Developmental Pathway Funding Scheme) is a key part of MRC’s Translational Research Strategy and supports the translation of fundamental discoveries toward benefits to human health. It funds the pre-clinical development and early clinical testing of novel therapeutics, devices and diagnostics, including "repurposing" of existing therapies.